This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
November 3–5, 2025
Vienna Congress and Convention Center, Vienna, AustriaNovember 11–12, 2025 | Digital Partnering

Tilmann Bürckstümmer
CSO at Myllia Biotechnology GmbH
Speaker

Profile

Tilmann is a CRISPR enthusiasts since the early days of CRISPR. Originally trained as a biochemist, he joined Haplogen as Principal Scientist and later became their CSO. Following the acquisition by Horizon Discovery, Tilmann served as Director R&D and, later, Head of Innovation where he oversaw Horizon's technology platform and innovation agenda. In 2018, he co-founded Myllia Biotechnology which focuses on single-cell CRISPR screens. He is also the CEO of bit.bio discovery, a joint venture between Vienna-based Myllia Biotechnology and Cambridge-based bit.bio. Tilmann is passionate about science and enjoys working with multi-disciplinary and multi-national teams.